Drug intelligence / Profile preview

latanoprost + timolol

Development stage
Phase 4
Lead developer
Pfizer
Modality
Small Molecules
Administration
Ophthalmic
01

Overview

**Latanoprost + timolol** is a fixed-dose ophthalmic combination of latanoprost, a prostaglandin F receptor agonist prodrug, and timolol, a nonselective beta-adrenergic receptor antagonist. It is administered as eye drops to lower elevated intraocular pressure in adults with open-angle glaucoma or ocular hypertension who have responded inadequately to topical monotherapy. Latanoprost increases aqueous-humor outflow, principally through the uveoscleral pathway, while timolol reduces aqueous-humor production; their complementary actions provide greater intraocular-pressure reduction than either component alone. Marketed formulations include preserved multidose products such as Xalacom and preservative-free unit-dose products such as Fixapost. ([labeling.pfizer.com](https://labeling.pfizer.com/ShowLabeling.aspx?id=15290))

Brand names
FixapostTavuVizilatan DuoXalacomXalcom适利加
Other names
latanoprost + timolollatanoprost + timolol maleatelatanoprost and timolol maleatelatanoprost/timololtimolol + latanoprost拉坦前列素 + 马来酸噻吗洛尔拉坦噻吗
02

Targets

ADRB1 (β1)ADRB2 (β2)PTGFR (Prostaglandin F2 alpha receptor)

Beyond the preview

Go deeper on latanoprost + timolol.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on latanoprost + timolol.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call